Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA4 | P54764 | 3/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | ILK | Q13418 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329341 | 0.92 | EPHA4 (0.66) | EPHA4CDK2FLT3CCNA1HRH4 | |
| SCHEMBL13360782 | 0.87 | EPHA4 (0.45) | EPHA4HSP90AB1ACHETLR8ILK | |
| SCHEMBL13329564 | 0.87 | EPHA4 (0.45) | EPHA4HSP90AB1ACHETLR8ILK | |
| SCHEMBL13329315 | 0.83 | EPHA4 (0.62) | EPHA4CDK2FLT3CCNA1HRH4 | |
| SCHEMBL13329319 | 0.81 | EPHA4 (0.44) | EPHA4FLT3 | |
| SCHEMBL13329333 | 0.80 | EPHA4 (0.45) | EPHA4CDK2FLT3CCNA1ACHE | |
| SCHEMBL13329321 | 0.80 | HTR7 (0.43) | EPHA4FLT3 | |
| SCHEMBL13329326 | 0.79 | EPHA4 (0.45) | EPHA4CDK2FLT3CCNA1BCHE | |
| SCHEMBL13329614 | 0.79 | EPHA4 (0.64) | EPHA4CDK2FLT3CCNA1BCHE | |
| SCHEMBL13360787 | 0.79 | EPHA4 (0.53) | EPHA4CDK2FLT3CCNA1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | EPHA4 1/4885HSP90AB1 3293/4885CDK2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.